How Peptides Degrade: Oxidation, Deamidation and More

Peptide degradation is the gradual chemical or physical change of a peptide into something other than the intended molecule, and the most common routes are oxidation, deamidation, hydrolysis and aggregation. Which pathways matter most depends on the peptide's amino acid sequence and on its environment: temperature, pH, moisture, light and oxygen. Understanding these pathways explains why peptides are stored and tested the way they are.

Key Takeaways

• Scientists group degradation into chemical instability (bonds change) and physical instability (shape or clumping changes, without new chemical bonds) [1].
• The amino acid sequence largely decides which pathways are likely. For example, methionine and cysteine are prone to oxidation, and asparagine followed by glycine is a well-known deamidation "hot spot" [2][3].
• Heat, moisture, pH, light, oxygen and trace metals can all speed up degradation [2][4].
• Degradation products appear as impurities on HPLC and mass spectrometry, which is why these tests are repeated over time in stability studies [5].
• Degradation in a vial is different from breakdown in the body, which mainly involves enzymes and kidney clearance [6].

Chemical vs. Physical Instability

A classic review of protein pharmaceuticals, still widely cited, divides instability into two families [1]:

• Chemical instability: the molecule's covalent bonds change, creating a new chemical entity. Examples include deamidation, oxidation, racemization, beta-elimination and proteolysis (breaking of the peptide backbone).
• Physical instability: the molecule's structure or state changes without new chemical bonds, for example aggregation, precipitation, denaturation, and adsorption (sticking) to surfaces.

A later update of that review emphasises that the two are linked: a chemical change can make a molecule more likely to aggregate, and vice versa [7].

For synthetic peptides specifically, the European Medicines Agency lists the following pathways that can form degradation products: oxidation, hydrolysis, isomerisation, deamidation, cyclic imide (aspartimide) formation, diketopiperazine and pyroglutamic acid formation, beta-elimination, condensation, disulfide cleavage or exchange, and acetylation [5]. (This is an EU guideline for medicines, applicable since 1 June 2026; other jurisdictions set their own requirements.)

The Main Chemical Pathways

Oxidation

Oxidation is one of the major chemical degradation pathways for protein and peptide drugs. The most susceptible amino acids are methionine, cysteine, histidine, tryptophan and tyrosine [2]. Oxidation can be:

• caused by contaminating oxidants such as peroxides,
• catalysed by trace transition metal ions, or
• triggered by light [2].

pH, temperature and buffer composition also influence the rate [2]. Oxidation can reduce biological activity. Interestingly, the best protective strategy depends on the mechanism: antioxidants can help against some types of oxidation, while for metal-catalysed oxidation, chelating agents (which bind metals) may be more appropriate [2].

Deamidation

Deamidation is the loss of an amide group from the side chain of asparagine (Asn) or glutamine (Gln), converting it into an acidic residue. It changes the peptide's charge and can change its structure.

A landmark study using synthetic peptides showed how fast this can be. A model hexapeptide containing the sequence Asn-Gly deamidated with a half-life of only 1.4 days at 37°C and pH 7.4, via a ring-shaped intermediate called a succinimide [3]. That intermediate then produced a mixture of products, including the unusual isoaspartyl form and D-amino acid versions. Replacing the glycine next to asparagine with a bulkier residue slowed the reaction 33- to 50-fold [3]. This is why sequence matters so much: the neighbouring amino acid can change the rate dramatically.

Later work measured deamidation rates for hundreds of asparagine-containing model peptide sequences, providing reference data for predicting which sequences are most vulnerable [8].

Hydrolysis and backbone cleavage

Hydrolysis means breaking a bond using water. In peptides, this can cut the backbone into shorter fragments. Asparagine and aspartic acid residues are known "hot spots" for non-enzymatic degradation, and backbone cleavage products have been observed in some asparagine-containing model peptides [3]. The EMA lists hydrolysis and Asp-containing sequences among the pathways to consider for synthetic peptides [5].

Isomerisation and racemisation

Isomerisation changes how atoms are connected without adding or removing any (for example, aspartate converting to isoaspartate). Racemisation converts the natural L-form of an amino acid into its mirror-image D-form [3]. These products can have the same mass as the original peptide, which makes them hard to detect by mass spectrometry alone. The EMA notes that controlling diastereomers may require specific analytical methods [5].

Other sequence-specific reactions

• Diketopiperazine formation: the first two amino acids at the start of a peptide chain can cyclise and break away [5].
• Pyroglutamic acid formation: an N-terminal glutamine or glutamic acid can cyclise [5].
• Disulfide exchange: in peptides with disulfide bridges, the bridges can break or reform in the wrong places [5].

Physical Pathway: Aggregation

Aggregation is when peptide molecules stick together, forming anything from small soluble clusters to large, highly ordered fibrils. A review from the University of Cambridge describes the many factors involved, including sequence, concentration, pH, net charge, excipients, surfaces, impurities, chemical degradation, temperature, agitation, pressure and lyophilisation [9].

Aggregation matters because aggregates can reduce the amount of active peptide available, and regulators take high-molecular-weight impurities (such as dimers, oligomers and aggregates) seriously. The EMA expects them to be investigated and specifically identified rather than lumped under a vague label [5].

What Speeds Up Peptide Degradation?

For practical context on these factors, see peptide storage: temperature, light and moisture.

Degradation in a Vial vs. Breakdown in the Body

These are often confused. In storage, degradation is mostly driven by the chemical and physical pathways above. In the body, peptides are mainly broken down by enzymes called proteases and removed by the kidneys. A review of peptide and protein drugs notes that short plasma half-lives are commonly due to fast renal clearance and enzymatic degradation in the circulation [6]. The same review gives a well-known example: octreotide, a shortened analogue of the hormone somatostatin that includes a D-amino acid, has a plasma half-life of about 1.5 hours compared with only a few minutes for somatostatin [6]. Our guides to peptide half-life and how peptides work in the body explore this further.

How Laboratories Detect Degradation

Degradation products usually show up as extra peaks or changed peak areas in HPLC testing, and as unexpected masses in mass spectrometry. Some changes, such as deamidation, shift the mass only slightly, while others, such as racemisation, do not change mass at all, so a combination of methods is often needed [3][5].

For medicines, the EMA expects forced degradation studies: samples are deliberately stressed (for example with heat, light or oxidants) to learn how the peptide breaks down and to confirm that the analytical methods can detect the resulting products [5]. Stability studies then track these impurities over the product's shelf life.

Frequently Asked Questions

What is the most common way peptides degrade?

It depends on the sequence. Peptides containing methionine or cysteine are prone to oxidation; those with asparagine, especially next to glycine, are prone to deamidation [2][3]. Aggregation can affect many peptides.

Does a degraded peptide look different?

Often not. Many degradation products are invisible to the eye and can only be detected with analytical techniques such as HPLC and mass spectrometry.

What is deamidation in simple terms?

It is a reaction where asparagine or glutamine loses an amide group and becomes an acidic amino acid. It changes the peptide's charge and can affect its structure and activity [3].

Can degradation be completely prevented?

No, but it can be slowed through formulation choices (such as pH and buffer selection), drying, cold storage, and protection from light and oxygen [2][4].

Is peptide degradation in the body the same as degradation in storage?

No. In the body, enzymes and kidney clearance dominate, whereas in storage, chemical and physical instability are the main concerns [6].

References

1. Manning MC, Patel K, Borchardt RT. Stability of protein pharmaceuticals. Pharm Res. 1989;6(11):903-918. https://doi.org/10.1023/a:1015929109894 ↗
2. Li S, Schöneich C, Borchardt RT. Chemical instability of protein pharmaceuticals: mechanisms of oxidation and strategies for stabilization. Biotechnol Bioeng. 1995;48(5):490-500. https://doi.org/10.1002/bit.260480511 ↗
3. Geiger T, Clarke S. Deamidation, isomerization, and racemization at asparaginyl and aspartyl residues in peptides. J Biol Chem. 1987;262(2):785-794. https://pubmed.ncbi.nlm.nih.gov/3805008/ ↗
4. Nugrahadi PP, Hinrichs WLJ, Frijlink HW, Schöneich C, Avanti C. Designing formulation strategies for enhanced stability of therapeutic peptides in aqueous solutions: a review. Pharmaceutics. 2023;15(3):935. https://doi.org/10.3390/pharmaceutics15030935 ↗
5. European Medicines Agency. Guideline on the Development and Manufacture of Synthetic Peptides (EMA/CHMP/CVMP/QWP/367182/2025). https://www.ema.europa.eu/en/development-manufacture-synthetic-peptides-scientific-guideline ↗
6. Werle M, Bernkop-Schnürch A. Strategies to improve plasma half life time of peptide and protein drugs. Amino Acids. 2006;30(4):351-367. https://doi.org/10.1007/s00726-005-0289-3 ↗
7. Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544-575. https://doi.org/10.1007/s11095-009-0045-6 ↗
8. Robinson NE, Robinson AB. Molecular clocks. Proc Natl Acad Sci U S A. 2001;98(3):944-949. https://doi.org/10.1073/pnas.98.3.944 ↗
9. Zapadka KL, Becher FJ, Gomes Dos Santos AL, Jackson SE. Factors affecting the physical stability (aggregation) of peptide therapeutics. Interface Focus. 2017;7(6):20170030. https://doi.org/10.1098/rsfs.2017.0030 ↗
10. Kerwin BA, Remmele RL Jr. Protect from light: photodegradation and protein biologics. J Pharm Sci. 2007;96(6):1468-1479. https://doi.org/10.1002/jps.20815 ↗

This article is for educational purposes only and is not medical advice. For health decisions, consult a qualified healthcare professional, and for regulatory questions, consult the medicines regulator in your jurisdiction.